Rafael Holdings (RFL) Stock Analysis & Winston Score
Rafael Holdings is a small holding company based in New Jersey. It owns two main things: commercial real estate properties in New Jersey and Israel, and minority stakes in early-stage biotech companies. The biotech investments focus on cancer treatment research, including a drug development company called Rafael Pharmaceuticals. The company earns rental income from its real estate properties, but most of its value is tied to whether its biotech investments succeed. It operates primarily in the United States and Israel and has a market cap of roughly $100 million. The extremely negative operating margin reflects heavy spending relative to its small revenue base, which is a common pattern for holding companies with unproven drug-development assets. The biggest risk is that early-stage drug development is expensive and uncertain — if the biotech investments fail to produce approved treatments, the company has limited other income sources to fall back on.
Winston Score: 31/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $2.15
Market Cap: $79M
Sector: Real Estate
Industry: Real Estate - Services
